.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:40PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

COMPLETE BLOOD COUNT;CBC*

Hemoglobin* 15.00 g/dL 13.00 - 17.00

(Photometry)

Packed Cell Volume (PCV)* 44.40 % 40.00 - 50.00

(Calculated)

RBC Count* 5.31 mill/mm3 4.50 - 5.50

(Electrical Impedence)

MCV* 83.60 fL 83.00 - 101.00

(Electrical Impedence)

MCH* 28.30 pg 27.00 - 32.00

(Calculated)

MCHC* 33.80 g/dL 31.50 - 34.50

(Calculated)

Red Cell Distribution Width (RDW)* 15.10 % 11.60 - 14.00

(Electrical Impedence)

Total Leukocyte Count (TLC)* 5.50 thou/mm3 4.00 - 10.00

(Electrical Impedence)

Differential Leucocyte Count (DLC)

(VCS Technology)
Segmented Neutrophils* 58.70 % 40.00 - 80.00
Lymphocytes* 25.00 % 20.00 - 40.00
Monocytes* 10.10 % 2.00 - 10.00
Eosinophils* 5.60 % 1.00 - 6.00
Basophils* 0.60 % <2.00
Absolute Leucocyte Count
(Calculated)
Neutrophils* 3.23 thou/mm3 2.00 - 7.00
Lymphocytes* 1.38 thou/mm3 1.00 - 3.00
Monocytes* 0.56 thou/mm3 0.20 - 1.00
Eosinophils* 0.31 thou/mm3 0.02 - 0.50
Basophils* 0.03 thou/mm3 0.02 - 0.10
Platelet Count* 245.0 thou/mm3 150.00 - 410.00
(Electrical impedence)

Mean Platelet Volume* 7.7 fL 6.5 - 12.0

(Electrical Impedence)

Note

*161355336*
Page 1 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:40PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

1. As per the recommendation of International council for Standardization in Hematology, the differential
leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of
blood

2. Test conducted on EDTA whole blood

*161355336*
Page 2 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:43PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

LIPID PROFILE, BASIC, SERUM*

Cholesterol Total* 216 mg/dL <200

(CHO-POD)

Triglycerides* 280 mg/dL <150

(GPO-POD)

HDL Cholesterol* 44 mg/dL >40

(Enz Immunoinhibition)

LDL Cholesterol,Direct* 135 mg/dL <100

(Enz Selective protection)

VLDL Cholesterol* 56 mg/dL <30

(Calculated)

Non-HDL Cholesterol* 172 mg/dL <130

(Calculated)

Interpretation
-----------------------------------------------------------------------------------
| NATIONAL LIPID | TOTAL | TRIGLYCERIDE | LDL CHOLESTEROL |NON HDL |
| ASSOCIATION | CHOLESTEROL | in mg/dL | in mg/dL |CHOLESTEROL |
| RECOMMENDATIONS | in mg/dL | | |in mg/dL |
| (NLA-2014) | | | | |
|-------------------|---------------|--------------|-----------------|--------------|
| Optimal | <200 | <150 | <100 | <130 |
|-------------------|---------------|--------------|-----------------|--------------|
| Above Optimal | - | - | 100- 129 | 130 - 159 |
|-------------------|---------------|--------------|-----------------|--------------|
| Borderline High | 200-239 | 150-199 | 130-159 | 160 - 189 |
|-------------------|---------------|--------------|-----------------|--------------|
| High | >=240 | 200-499 | 160-189 | 190 - 219 |
|-------------------|---------------|--------------|-----------------|--------------|
| Very High | - | >=500 | >=190 | >=220 |
-----------------------------------------------------------------------------------

Note
1. Measurements in the same patient can show physiological & analytical variations. Three serial
samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL
Cholesterol.
2. Lipid Association of India (LAI) recommends screening of all adults above the age of 20 years for
Atherosclerotic Cardiovascular Disease (ASCVD) risk factors especially lipid profile. This should be
PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*161355336*
Page 3 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:43PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

done earlier if there is family history of premature heart disease, dyslipidemia, obesity or other risk
factors
3. Indians tend to have higher triglyceride levels & Lower HDL cholesterol combined with small dense
LDL particles, a pattern known as atherogenic dyslipidemia
4. Non HDL Cholesterol comprises the cholesterol carried by all atherogenic particles, including LDL,
IDL, VLDL & VLDL remnants, Chylomicron remnants & Lp(a)
5. The term LDL Cholesterol includes contribution of cholesterol from Lp(a), IDL & core LDL. Although
IDL and Lp(a) contributes only very few mg/dL to LDL cholesterol but their contribution can be
significant in patients with increased high IDL or Lp(a) concentration
6. LAI recommends LDL cholesterol as primary target and Non HDL cholesterol as co-primary
treatment target. The goal for Non HDL Cholesterol in those with increased triglyceride is 30 mg/dL
above that set for LDL Cholesterol.
7. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals
have been achieved
8. Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered among
patients with moderate risk for ASCVD for risk refinement

Risk Stratification of ASCVD by Lipid Association of India 2016

-----------------------------------------------------------------------------------------------
| Major ASCVD Risk Factors |
|-----------------------------------------------------------------------------------------------|
| 1. Age >= 45 years in males and >= 55 years females |
| 2. Family h/o premature ASCVD(< 55 years of age in a male first degree relative or |
| <65 years of age in a female first degree relative) |
| 3. Current Cigarette smoking or tobacco use |
| 4. High blood pressure |
| 5. Low HDL |
|-----------------------------------------------------------------------------------------------|
| ASCVD Risk Categories |
|-----------------------------------------------------------------------------------------------|
| Risk Category | Conventional Risk markers | Non-Conventional Risk |
| | | markers (Optional) |
|---------------|------------------------------------------------|------------------------------|
| Very High | 1. Established ASCVD | None |
| Risk | 2. Diabetes with 2 or more major ASCVD risk | |
| | factors and/or evidence of end organ damage | |
| | 3. Familial Homozygous hypercholesterolemia | |
|---------------|------------------------------------------------|------------------------------|
| High Risk | | 1. Coronary artery calcium, |
| | 1. >=3 major ASCVD risk factors | CAC score >=300 AU |
| | 2. Diabetes with 0-1 major risk factor and no | 2. Lp(a)> = 50 mg/dL |
| | evidence of end organ damage | 3. Non stenotic carotid |
| | 3. CKD stage 3 B or 4 | plaque |
| | 4. Familial Hypercholesterolemia( other than | |
| | Familial Homozygous hypercholesterolemia) | |
| | 5. Extreme of a single factor e.g. LDL | |
| | Cholesterol >190 mg/dL,Heavy smoker, | |
| | strong family h/o premature ASCVD | |
PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*161355336*
Page 4 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:43PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

|---------------|------------------------------------------------|------------------------------|
| Moderate risk | Any 2 major ASCVD risk factors | 1. Coronary artery calcium, |
| | | CAC score 100-299 AU |
| | | 2. Lp(a) 20-49 mg/dL |
| | | 3. Metabolic syndrome |
|---------------|------------------------------------------------|------------------------------|
| Low risk | 0-1 major ASCVD risk factors | None |
-----------------------------------------------------------------------------------------------

Treatment Goals as per Lipid Association of India 2016

-----------------------------------------------------------------------------------------
| | CONSIDER THERAPY | TREATMENT GOAL |
| |-------------------------------------|-------------------------------------|
| RISK CATEGORY| LDL CHOLESTEROL| NON HDL CHLOESTEROL| LDL CHOLESTEROL| NON HDL CHLOESTEROL|
| | (LDL-C)(mg/dL) | (NON HDL-C) (mg/dL)| (LDL-C)(mg/dL) |(NON HDL-C) (mg/dL |
|--------------|----------------|--------------------|----------------|--------------------|
| Very High | >=50 | >=80 | <50 | <80 |
|--------------|----------------|--------------------|----------------|--------------------|
| High | >=70 | >=100 | <70 | <100 |
|--------------|----------------|--------------------|----------------|--------------------|
| Moderate | >=100 | >=130 | <100 | <130 |
|--------------|----------------|--------------------|----------------|--------------------|
| Low | >=130* | >=160* | <100 | <130 |
------------------------------------------------------------------------------------------
* In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months

LIVER PANEL 1; LFT,SERUM

AST (SGOT)* 31.0 U/L 15.00 - 40.00

(IFCC without P5P)

ALT (SGPT)* 45.0 U/L 10.00 - 49.00

(IFCC without P5P)

AST:ALT Ratio 0.69 <1.00

(Calculated)

GGTP* 43.0 U/L 0 - 73

(IFCC)

Alkaline Phosphatase (ALP)* 73.00 U/L 30.00 - 120.00

(IFCC-AMP)

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*161355336*
Page 5 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:43PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

Bilirubin Total* 0.69 mg/dL 0.30 - 1.20
(Oxidation)

Bilirubin Direct* 0.22 mg/dL <0.3

(Oxidation)

Bilirubin Indirect* 0.47 mg/dL <1.10

(Calculated)

Total Protein* 7.30 g/dL 5.70 - 8.20

(Biuret)

Albumin* 4.80 g/dL 3.20 - 4.80

(BCG)

A : G Ratio* 1.92 0.90 - 2.00

(Calculated)

Note
1. In an asymptomatic patient, Non alcoholic fatty liver disease (NAFLD) is the most common cause of
increased AST, ALT levels. NAFLD is considered as hepatic manifestation of metabolic syndrome.
2. In most type of liver disease, ALT activity is higher than that of AST; exception may be seen in Alcoholic
Hepatitis, Hepatic Cirrhosis, and Liver neoplasia. In a patient with Chronic liver disease, AST:ALT
ratio>1 is highly suggestive of advanced liver fibrosis.
3. In known cases of Chronic Liver disease due to Viral Hepatitis B & C, Alcoholic liver disease or NAFLD,
Enhanced liver fibrosis (ELF) test may be used to evaluate liver fibrosis.
4. In a patient with Chronic Liver disease, AFP and Des-gamma carboxyprothrombin (DCP)/PIVKA II can
be used to assess risk for development of Hepatocellular Carcinoma.

KIDNEY PANEL; KFT,SERUM

Urea* 17.00 mg/dL 13.00 - 43.00

(Urease UV)

Creatinine* 0.73 mg/dL 0.70 - 1.30

(Modified JaffeKinetic)

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*161355336*
Page 6 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:43PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

Uric Acid* 5.60 mg/dL 3.50 - 7.20
(Uricase)

Calcium, Total* 9.80 mg/dL 8.70 - 10.40

(Arsenazo III)

Phosphorus* 3.40 mg/dL 2.40 - 5.10

(Molybdate UV)

Alkaline Phosphatase (ALP)* 73.00 U/L 30.00 - 120.00

(IFCC-AMP)

Total Protein* 7.30 g/dL 5.70 - 8.20

(Biuret)

Albumin* 4.80 g/dL 3.20 - 4.80

(BCG)

A : G Ratio* 1.92 0.90 - 2.00

(Calculated)

Sodium* 145.00 mEq/L 136.00 - 145.00

(Indirect ISE)

Potassium* 4.10 mEq/L 3.50 - 5.10

(Indirect ISE)

Chloride* 105.00 mEq/L 98.00 - 107.00

(Indirect ISE)

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*161355336*
Page 7 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:46PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

URINE EXAMINATION, ROUTINE; URINE, R/E*
(Automated Strip Test, Microscopy)

Physical

Colour Pale Yellow Pale yellow

Specific Gravity 1.010 1.001 - 1.030

pH 5 5.0 - 8.0

Chemical

Proteins Negative Negative

Glucose Present 4+(2.0 g/dL) Negative

Ketones Negative Negative

Bilirubin Negative Negative

Urobilinogen Negative Negative

Leucocyte Esterase Negative Negative

Nitrite Negative Negative

Microscopy

R.B.C. Negative 0.0 - 2.0 RBC/hpf

Pus Cells Negative 0-5 WBC / hpf

Epithelial Cells 0-1 Epi Cells/hpf 0.0 - 5.0 Epi

cells/hpf
Casts None seen None seen/Lpf

Crystals None seen None seen

Others None seen None seen

Result Rechecked,
Please Correlate Clinically.

PatientReportSCSuperPanel.URINE_EXAMINATION_SC (Version: 6) Page 8 of 14

*161355336*
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:48PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD*
(HPLC, NGSP certified)

HbA1c* 7.0 % 4.00 - 5.60

Estimated average glucose (eAG)* 154 mg/dL

Interpretation
HbA1c result is suggestive of Diabetes/ well controlled Diabetes in a known Diabetic

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered,
particularly when the HbA1C result does not correlate with the patient’s blood glucose levels.

---------------------------------------------------------------------------------
| FACTORS THAT INTERFERE WITH HbA1C | FACTORS THAT AFFECT INTERPRETATION |
| MEASUREMENT | OF HBA1C RESULTS |
|--------------------------------------|------------------------------------------|
| Hemoglobin variants,elevated fetal | Any condition that shortens erythrocyte |
| hemoglobin (HbF) and chemically | survival or decreases mean erythrocyte |
| modified derivatives of hemoglobin | age (e.g.,recovery from acute blood loss,|
| (e.g. carbamylated Hb in patients | hemolytic anemia, HbSS, HbCC, and HbSC) |
| with renal failure) can affect the | will falsely lower HbA1c test results |
| accuracy of HbA1c measurements | regardless of the assay method used.Iron |
| | deficiency anemia is associated with |
| | higher HbA1c |
---------------------------------------------------------------------------------

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*161355336*
Page 9 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:50PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

GLUCOSE, FASTING (F), PLASMA* 133.00 mg/dL 70 - 100
(Hexokinase)

BLOOD GROUP, ABO & RH TYPING AUTOMATED

(Erythrocyte Magnetized Technology)

ABO Group AB

Rh Factor Positive

Note: 1. Both forward and reverse grouping performed

2. Test conducted on EDTA whole blood
VITAMIN B12; CYANOCOBALAMIN, SERUM* 214.00 pg/mL 211.00 - 911.00
(CLIA)

Notes
1. Interpretation of the result should be considered in relation to clinical circumstances.
2. It is recommended to consider supplementary testing with plasma Methylmalonic acid (MMA) or
plasma homocysteine levels to determine biochemical cobalamin deficiency in presence of clinical
suspicion of deficiency but indeterminate levels. Homocysteine levels are more sensitive but MMA is
more specific

3. False increase in Vitamin B12 levels may be observed in patients with intrinsic factor blocking
antibodies, MMA measurement should be considered in such patients

4. The concentration of Vitamin B12 obtained with different assay methods cannot be used
interchangeably due to differences in assay methods and reagent specificity

VITAMIN D, 25 - HYDROXY, SERUM* 48.17 nmol/L 75.00 - 250.00

(CLIA)

Interpretation
-------------------------------------------------------------
| LEVEL | REFERENCE RANGE | COMMENTS |
| | IN nmol/L | |
|---------------|-----------------|---------------------------|
| Deficient | < 50 | High risk for developing |
| | | bone disease |
|---------------|-----------------|---------------------------|
| Insufficient | 50-74 | Vitamin D concentration |
| | | which normalizes |
| | | Parathyroid hormone |
| | | concentration |
|---------------|-----------------|---------------------------|
PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*161355336*
Page 10 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:50PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

| Sufficient | 75-250 | Optimal concentration |
| | | for maximal health benefit|
|---------------|-----------------|---------------------------|
| Potential | >250 | High risk for toxic |
| intoxication | | effects |
-------------------------------------------------------------

Note
· The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
· 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
· Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
· It shows seasonal variation, with values being 40-50% lower in winter than in summer.
· Levels vary with age and are increased in pregnancy.
· A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available

Comments
Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency
in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and
Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major
circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

Decreased Levels
· Inadequate exposure to sunlight
· Dietary deficiency
· Vitamin D malabsorption
· Severe Hepatocellular disease
· Drugs like Anticonvulsants
· Nephrotic syndrome

Increased levels
Vitamin D intoxication

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*161355336*
Page 11 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:53PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

THYROID PROFILE,TOTAL, SERUM

(CLIA)
T3, Total* 1.45 ng/mL 0.60 - 1.81

T4, Total* 15.50 µg/dL 5.01 - 12.45

TSH* 3.47 µIU/mL 0.550 - 4.780

Note
1. TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a
minimum between 6-10 pm . The variation is of the order of 50% . hence time of the day has
influence on the measured serum TSH concentrations.
2. Alteration in concentration of Thyroid hormone binding protein can profoundly affect Total T3 and/or
Total T4 levels especially in pregnancy and in patients on steroid therapy.
3. Unbound fraction ( Free,T4 /Free,T3) of thyroid hormone is biologically active form and correlate
more closely with clinical status of the patient than total T4/T3 concentration
4. Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in
some individuals

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*161355336*
Page 12 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:53PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

Dr Ajay Gupta Dr Gurleen Oberoi Dr Himangshu Mazumdar Dr Jatin Munjal

MD, Pathology DM(Hematopathology), MD, MD, Biochemistry MD,Pathology
Technical Director - Hematology & DNB,MNAMS Sr. Consultant Biochemist Consultant Pathologist
Immunology Consultant & Technical Lead NRL - Dr Lal PathLabs Ltd Dr Lal PathLabs Ltd
NRL - Dr Lal PathLabs Ltd -Hematopathology
NRL - Dr Lal PathLabs Ltd

Dr.Kamal Modi Dr Ritu Nayar Dr Nimmi Kansal Dr Sarita Kumari Lal

MD, Biochemistry MD, Microbiology MD, Biochemistry MD, Pathology
Consultant Biochemist Deputy HOD - Microbiology & Serology Technical Director - Clinical Chemistry Consultant Pathologist
NRL - Dr Lal PathLabs Ltd NRL - Dr Lal PathLabs Ltd & Biochemical Genetics Dr Lal PathLabs Ltd
NRL - Dr Lal PathLabs Ltd

Dr Shalabh Malik Dr Sunanda

MD, Microbiology MD, Pathology
Technical Director - Microbiology, Consultant Pathologist
Infectious Disease Serology and Dr Lal PathLabs Ltd
Clinical Pathology

AHEEEHAPMKHIBIANLKIDOJNCBILLJCECCKLCIKPKNKEDFBFAPPAHEEEHA
BNFFFNBPAPBLJOAGFGEHFGAPAOAHFHALBKNOBCJONLEKMCJGMPBNFFFNB
CIEGDHFJPONELBFOPFIAAJHFJGFEHEDFLKPHENFLMLKIOEFLBLHDEHANP
DJBAOCFNBKJIEDIOFJNELFMFAFPKBLBFJIFEOBPAKCLJPDNLILFBKEMEK
KCDKLHFJOFJFDIAPNJCCKPJHLENNMBAHKKMBEKEIPLKGKPNGKFFFOKIMG
LDCBBEFMNICGDJFKIDILKIPBADHFOFAINDFCBKDKALIKOMNALNEJPOEKL
DLIMIJFJILOJOFDIEKMCAGHHIHAFJBAKODMPBLMEKJCHKJNJAJNJMDILD
NJJJAMFNBLOBGEHJGANHDJBILLBMFMBBIFCCAMNNIIKNOPNOBNFNBHILL
NKBKHGFNFHDGFAABGMOIHMAKHEEFEKFBJFFKBKPFOOBIOCNKDJPHNEKLJ
MPLOIHFCEDBJJDCHFHCFGPNJJDFKPNJHKEPFEJHLNKCKIGEOCFKKHICJK
GAIKOLFLGKCBMOAMPNNIPJEEINMGMJEBJMFEBFOFPNDMKPFKEPCIGCAEO
MKICGJFCPLDAIEPMHHGCAMAEIEOPPFOFBGPPBLNOOLJBIKNJPKONHDICL
MNNNNNEPKEAGCKKJOCFLHBMHJBAHFHABPKPFCMNLMKJCLFNIAHFHAHIKL
APBBBPAPBMMAEJBGCMBKCNCFAHGCHHCAONFEPLPGOLMHNLNNEDFHDBKHH
HHHHHHHPHHHPHPPHHPPPPPHPPHPPPPPPPPPHHHHPPHHHPHPHHHHHPHPHP

Result/s to follow:
MICROALBUMIN/ALBUMIN : CREATININE RATIO (ACR), URINE

* Test conducted under NABL scope MC-2113,LPL-NATIONAL REFERENCE LAB at NEW DELHI

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*161355336*
Page 13 of 14
.

LPL - PSC Shakti Nagar Home Visit

DELHI, DEL
DELHI

Name : Mr. SANJAY SHARMA Collected : 30/4/2022 7:19:00AM

Received : 30/4/2022 7:25:15AM
Lab No. : 161355336 Age: 56 Years Gender: Male Reported : 30/4/2022 9:51:53PM
A/c Status : P Ref By : SELF Report Status : Interim

Test Name Results Units Bio. Ref. Interval

IMPORTANT INSTRUCTIONS

ŸTest results released pertain to the specimen submitted .ŸAll test results are dependent on the quality of the sample received by the Laboratory .
ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring
Physician.ŸSample repeats are accepted on request of Referring Physician within 7 days post reporting.ŸReport delivery may be delayed due to
unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost for derivation of exact value .
Kindly submit request within 72 hours post reporting.ŸTest results may show interlaboratory variations .ŸThe Courts/Forum at Delhi shall have
exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid for medico legal purposes .
ŸContact customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

*161355336*
Page 14 of 14